Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

This study is testing a new drug called SHR-8068 for people with advanced non-small cell lung cancer (NSCLC) — the most common type of lung cancer. The drug is being tested both alone and in combination with other treatments, and the study aims to find the right dose and understand how well it works. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with non-small cell lung cancer that cannot be cured with surgery - Your cancer has progressed after standard treatments, or you have not yet received chemotherapy for advanced disease - You are in good enough physical condition to participate (able to carry out light work or self-care) - Your liver, kidneys, and blood counts are functioning adequately **You may NOT be eligible if...** - Your cancer has spread to the brain in an uncontrolled way - You have significant heart conditions - You have active autoimmune disease - You have received prior immunotherapy that caused serious side effects - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.